Health condition
Clonal cytopenia meaning
Clonal cytopenia of undetermined significance (CCUS) means low blood counts and a clonal mutation coexist, but marrow findings do not yet meet criteria for myelodysplasia; it carries a higher progression risk than CHIP and warrants structured haematology follow-up.
Why trust this guide
- 01
Editorial team
Written by our editorial team from the UK sources listed on each page.
- 02
Sourced from guidance
Checked against current NHS and UK specialist society guidance at the time of review.
- 03
Current for 2026
Reviewed on 2026-09-27 with the next review scheduled for 2027-09-27.
Key facts
The essentials at a glance.
The symptoms to recognise, when to seek help, which specialist to see, and what treatment usually involves.
-
CCUS = unexplained cytopenia + clonal mutation, without diagnostic MDS features on marrow
-
Progression risk exceeds CHIP and depends on which mutations, how many, and their size
-
High-risk patterns include splicing-factor mutations and multiple or large clones
-
Follow-up typically means counts every few months and reassessment if they drift
Understanding the condition
What it is and what happens next.
What causes it, how it is diagnosed, and the treatment routes available in the UK.
What it is and how it feels
CCUS occupies the borderland between innocent clonal ageing and myelodysplastic syndrome. The counts are genuinely low, a mutation confirms a clone is present, but the marrow lacks the dysplasia or blast excess that would name the disease. It is best understood as a risk state under surveillance: some patients remain stable for many years, while others declare MDS as the clone evolves.
Diagnosis and treatment routes
Modern practice grades that risk rather than treating the label: mutations in splicing factors such as SF3B1 or SRSF2, TP53 involvement, multiple mutations or high allele burdens all raise the likelihood of progression and tighten the monitoring interval. There is no treatment to start today outside trials - the value lies in catching evolution early, when the full range of MDS therapies and transplant timing remain open. In many parts of the UK, routine NHS referrals for this kind of problem can take months, whereas an initial appointment with a private consultant is typically available within around two weeks.
Seeing a specialist
Who to see, and how quickly you can be seen.
The specialist for this condition is usually a consultant haematologist. Your GP can refer you on the NHS, or you can arrange a private consultation directly.
A quiet reminder
This guide is for information, not medical advice.
Your GP knows your history and can tell you which parts apply to you. If in doubt, see them - and seek urgent care for any of the emergency symptoms described above.
Frequently asked
Common questions about Clonal cytopenia meaning.
Quick, plain-English answers to what people ask us most.
-
What is clonal cytopenia of undetermined significance?
Clonal cytopenia of undetermined significance (CCUS) is a condition in which blood counts are persistently low (cytopenia) and specific genetic mutations associated with blood cancers are found in blood-forming cells, but without enough features to meet the diagnostic criteria for a defined blood cancer such as myelodysplastic syndrome. It represents an intermediate finding that requires monitoring rather than immediate treatment. It is increasingly recognised as more sensitive genetic testing becomes more widely used.
-
What causes CCUS?
It results from acquired genetic mutations occurring in blood-forming stem cells over a person's lifetime, giving rise to a population of blood cells with a shared genetic change (a 'clone'), combined with low blood counts from an as yet unclear cause. These mutations become more common with increasing age. The exact reasons why some people with these mutations develop clinically significant low blood counts while others do not are still being researched.
-
Is CCUS the same as a blood cancer?
No, CCUS is not itself a blood cancer, but it is considered a pre-cancerous or higher-risk state, since some people with CCUS go on to develop a defined blood cancer, such as myelodysplastic syndrome or acute leukaemia, over time. Not everyone with CCUS progresses to cancer, and progression risk varies depending on the specific mutations found and other individual factors. This is why ongoing haematology monitoring, rather than immediate treatment, is generally the appropriate approach.
-
How is CCUS monitored?
Monitoring typically involves regular blood tests to track blood counts over time, and sometimes repeat bone marrow examination or further genetic testing if there are signs of change, to check whether the condition remains stable or is evolving towards a defined blood cancer. The specific frequency of monitoring depends on individual risk factors identified through initial testing. Your haematology team will tailor a monitoring schedule appropriate to your specific findings.
-
Does CCUS need treatment?
Generally, no specific treatment is needed for CCUS itself, since it does not meet the criteria for an active blood cancer requiring treatment. Instead, the focus is on regular monitoring to detect any progression towards a defined condition needing treatment, allowing this to be identified and addressed promptly if and when it occurs. This watch-and-monitor approach is considered the appropriate standard of care for this finding.
-
When should I see a specialist?
If you have been told you have CCUS, or blood tests show persistent unexplained low counts with relevant genetic findings, haematology assessment and ongoing follow-up is recommended. NHS haematology referral can take several weeks; a private consultation is typically available within about 2 weeks for earlier specialist assessment and explanation of what this finding means for you specifically.